Quantum BioPharma Moves to Voluntarily Delist from Canadian Securities Exchange
QNTM sits 46% above its 52-week low of $2.07.
Summary
Quantum BioPharma applied to voluntarily delist its Class B shares from the Canadian Securities Exchange, with the last trading day expected September 4, 2026. Nasdaq remains the primary listing.
Key Events · Corporate Governance and Compliance · QNTM
-
Voluntary CSE Delisting
Quantum BioPharma applied to delist its Class B shares from the Canadian Securities Exchange, citing low trading volume and the cost of maintaining a dual listing.
-
Last Trading Day Set
Subject to CSE approval, the close of business on Friday, September 4, 2026, will be the last trading day for Class B shares on the CSE.
-
Nasdaq Remains Primary Market
The delisting does not affect the Nasdaq listing; Class B shares will continue trading on Nasdaq under the symbol QNTM.
-
Canadian Reporting Continues
The company will remain a reporting issuer in Canada and continue filing continuous disclosure documents on SEDAR+ and EDGAR.
Analysis · QNTM · Life Sciences
Quantum BioPharma is voluntarily delisting its Class B shares from the Canadian Securities Exchange, consolidating trading on Nasdaq. The company cites low CSE trading volume and the cost of maintaining a dual listing. This is a governance red flag because it reduces the number of public markets for the stock and concentrates liquidity risk on a single exchange, while also signaling that the company is cutting costs aggressively. The delisting is expected to take effect after September 4, 2026, subject to CSE approval.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNTM was trading at $3.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.6M. The 52-week trading range was $2.07 to $21.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.